Literature DB >> 11295593

The molecular pathogenesis of prostate cancer: Implications for prostate cancer prevention.

W G Nelson1, A M De Marzo, T L DeWeese.   

Abstract

Prostate cancer has become 1 of the most commonly diagnosed cancers in the United States and 1 of the leading causes of cancer death in North America and Western Europe. Survey studies of prostate tissues obtained at autopsy indicate that the development of life-threatening prostate cancer in the US likely occurs over decades. Insights from epidemiologic studies implicate environmental factors, principally dietary components, as major risk factors for prostate cancer development. An accumulating body of basic research data suggests that normal and neoplastic prostate cells may be subjected to a relentless barrage of genome-damaging stresses, and that dietary components and male sex steroids might modulate the level of genome threatening insults. Finally, over the past 5 years, analyses of somatic genome alterations in prostatic carcinoma cells have revealed that somatic inactivation of GSTP1, encoding the carcinogen-detoxification enzyme glutathione S-transferase pi, may serve as an initiating genome lesion for prostatic carcinogenesis. These diverse observations can be integrated into a transcendent mechanistic hypothesis for the pathogenesis of prostate cancer: normal prostate cells acquiring somatic GSTP1 defects may suffer chronic genome damage, influenced by dietary practices, that promote neoplastic transformation, while prostatic carcinoma cells, which characteristically contain defective GSTP1 alleles, remain susceptible to further genome-damaging stresses that promote malignant cancer progression. This hypothesized critical role for GSTP1 inactivation in the earliest steps of prostatic carcinogenesis provides several attractive opportunities for prostate cancer prevention strategies, including (1) restoration of GSTP1 function, (2) compensation for inadequate GSTP1 activity (via use of therapeutic inducers of other glutathione S-transferases (GST), and (3) abrogation or attenuation of genome-damaging stresses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11295593     DOI: 10.1016/s0090-4295(00)00939-0

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  19 in total

1.  Radiosensitivity and repair kinetics of gamma-irradiated leukocytes from sporadic prostate cancer patients and healthy individuals assessed by alkaline comet assay.

Authors:  Maryam Shahidi; Hossein Mozdarani; Wolfgang-Ulrich Mueller
Journal:  Iran Biomed J       Date:  2010-07

2.  Promoter methylation and differential expression of pi-class glutathione S-transferase in endometrial carcinoma.

Authors:  Queeny K Y Chan; Ui-Soon Khoo; Kelvin Y K Chan; Hextan Y S Ngan; Shan-Shan Li; Pui-Man Chiu; Li-Shan Man; Philip P C Ip; Wei-Cheng Xue; Annie N Y Cheung
Journal:  J Mol Diagn       Date:  2005-02       Impact factor: 5.568

Review 3.  Evolving strategies for prostate cancer chemoprevention trials.

Authors:  Ronald Lieberman
Journal:  World J Urol       Date:  2003-04-01       Impact factor: 4.226

4.  Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk.

Authors:  Jianfeng Xu; S Lilly Zheng; Akira Komiya; Josyf C Mychaleckyj; Sarah D Isaacs; Baoli Chang; Aubrey R Turner; Charles M Ewing; Kathleen E Wiley; Gregory A Hawkins; Eugene R Bleecker; Patrick C Walsh; Deborah A Meyers; William B Isaacs
Journal:  Am J Hum Genet       Date:  2002-12-06       Impact factor: 11.025

5.  DNA methyltransferase 3b silencing affects locus-specific DNA methylation and inhibits proliferation, migration and invasion in human hepatocellular carcinoma SMMC-7721 and BEL-7402 cells.

Authors:  Jia-Chen Wang; Zhao Wang; Yu-Xia Fan; Ya-Qing Si; Jia-Xiang Wang
Journal:  Oncol Lett       Date:  2015-03-26       Impact factor: 2.967

6.  Inflammation and atrophy precede prostatic neoplasia in a PhIP-induced rat model.

Authors:  Alexander D Borowsky; Karen H Dingley; Esther Ubick; Kenneth W Turteltaub; Robert D Cardiff; Ralph Devere-White
Journal:  Neoplasia       Date:  2006-09       Impact factor: 5.715

7.  Interleukin-driven insulin-like growth factor promotes prostatic inflammatory hyperplasia.

Authors:  Alana M Hahn; Jason D Myers; Eliza K McFarland; Sanghee Lee; Travis J Jerde
Journal:  J Pharmacol Exp Ther       Date:  2014-10-07       Impact factor: 4.030

8.  Peripheral mononuclear leukocyte DNA damage, plasma prolidase activity, and oxidative status in patients with benign prostatic hyperplasia.

Authors:  Ilhan Gecit; Ismail Meral; Mehmet Aslan; Abdurrahim Kocyigit; Hakim Celik; Abdullah Taskın; Mehmet Kaba; Necip Pirincci; Mustafa Gunes; Kerem Taken; Halit Demir; Mehmet Uyuklu; Kadir Ceylan
Journal:  Redox Rep       Date:  2014-12-31       Impact factor: 4.412

9.  Chronic bacterial inflammation induces prostatic intraepithelial neoplasia in mouse prostate.

Authors:  J E Elkahwaji; R J Hauke; C M Brawner
Journal:  Br J Cancer       Date:  2009-10-20       Impact factor: 7.640

10.  GSTP1 Loss results in accumulation of oxidative DNA base damage and promotes prostate cancer cell survival following exposure to protracted oxidative stress.

Authors:  Omar Y Mian; Mohamed H Khattab; Mohammad Hedayati; Jonathan Coulter; Budri Abubaker-Sharif; Julie M Schwaninger; Ravi K Veeraswamy; James D Brooks; Lisa Hopkins; Debika Biswal Shinohara; Brian Cornblatt; William G Nelson; Srinivasan Yegnasubramanian; Theodore L DeWeese
Journal:  Prostate       Date:  2015-10-08       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.